Development of the Proteasome Inhibitor Velcade™ (Bortezomib)

By J. Adams, M. Kauffman. Cancer Investigation, 2004

658 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/12d7f9cc9bc15d488865c2340fd7c83430467f93

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Ivan Dikic
2. David Frescas
3. M. Pagano

In Oncology

1. Ivan Dikic
2. M. Pagano

Citations in the corpus

• Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer (2008, background): “Previous attempts at targeting components of the degradation machinery have been successful for laboratory and clinical use, as observed with the effectiveness of the proteasome inhibitor bortezomib (Velcade) in multiple myelom”
• Ubiquitylation and cell signaling (2005, background): “The reversible proteasome inhibitor Bortezomib (Velcade) has shown positive results for the treatment of relapsed and refractory multiple myeloma and is the first proteasome inhibitor approved in clinics (Adams and Kauffman, 2004).”